Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranolazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranolazine SCHEMBL1534086 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124665 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL6391141 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL1495098 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL30296819 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL7933344 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL612077 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL14841986 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL230758 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL3462812 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6855 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| US-12569481-B2 | Methods of treatment for gastrointestinal motility disorders | VANDERBILT UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-5906988-A | PROTECTING MYOCARDIUM AGAINST GLOBAL ISCHAEMIC DAMAGE INDUCED BY CARDIOPLEGIA AND PROTECTING NEURONAL TISSUE AGAINST ISCHAEMIC DAMAGE RESULTING FROM CARDIAC OR NON-CARDIAC CONDITIONS COMPRISES ADMINISTERING RANOLAZINE OR DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1999-05-25 | — | — | US | claimed |
| EP-0407780-B1 | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult | SYNTEX INC (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0719558-A1 | Ranolazine and related piperazines for use in the treatment of shock conditions | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-07-03 | — | — | EP | claimed |
| EP-0714660-A1 | Ranolazine and related piperazines for protecting skeletal muscles | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-06-05 | — | — | EP | claimed |
| CN-1122571-A | High dosage formulations | SYNTEX INC (US) | 1996-05-15 | — | — | CN | claimed |
| US-5506229-A | SKELETAL AND MUSCLE DISORDERS | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1996-04-09 | — | — | US | claimed |
| EP-0697866-A1 | HIGH DOSE FORMULATIONS | SYNTEX (U.S.A.) INC. (US) | 1996-02-28 | — | — | EP | claimed |
| US-5472707-A | Melting and cooling, filling in liquefied form into a capsule form; mixed with excipients, croscarmellose sodium dispersant and sorbitol crystal retardant | SYNTEX (U.S.A.) INC. (US) | 1995-12-05 | — | — | US | claimed |
| WO-1994026266-A1 | HIGH DOSE FORMULATIONS | SYNTEX (U.S.A.) INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0407780-A2 | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult | SYNTEX PHARMACEUTICALS LTD. (GB) | 1991-01-16 | — | — | EP | claimed |